Novo Nordisk A/S’s US obesity sales force had just gathered in Las Vegas, NV, to prepare for the launch of its Wegovy (semaglutide) weight-loss drug when the company learned on 17 December that it would produce very little new product for at least six months due to manufacturing quality issues.
Initial sales exceeded all expectations. But production sharply declined after the contract manufacturing organization chosen for initial production responded to...





